更昔洛韦与缬更昔洛韦在移植中的药动学、药效学及治疗药物监测
本文综述了更昔洛韦和缬更昔洛韦在实体器官及干细胞移植受者中的临床药动学、暴露-效应关系及TDM工具。两药药动学在成人和儿童中描述充分且个体间变异大,药效学在成人中描述不足、儿童中极少。AUC0-24h似乎是疗效和毒性的最佳预测指标,TDM在成人中获益存争议,但在儿童中应考虑。
要点
- 更昔洛韦/缬更昔洛韦药动学个体间变异大,儿童变异更高。
- AUC0-24h似乎是疗效和毒性的最佳预测指标。
- TDM在成人中获益存争议,儿童应考虑;贝叶斯 estimator 可用于AUC指导剂量调整。
核心结论
- 更昔洛韦和缬更昔洛韦的药动学在成人和儿童中描述充分,但个体间变异大。
- 药效学在成人中描述不足,在儿童中极少描述。
- AUC0-24h似乎是疗效和毒性的最佳预测指标。
- TDM在成人患者中获益仍存争议,但在儿童中应考虑。
研究设计与样本
- 本文为广泛文献综述,纳入成人及儿童移植受者中更昔洛韦和缬更昔洛韦的临床药动学数据、疗效与安全性暴露-效应关系及TDM可用工具。
主要发现
- 更昔洛韦和缬更昔洛韦的药动学在成人和儿童中描述充分,常见高个体间变异。
- 药效学在成人中描述不足,在儿童中极少描述。
- 平均24小时浓度-时间曲线下面积(AUC0-24h)似乎是疗效和毒性的最佳预测指标。
关键数值与推荐
- AUC0-24h似乎是疗效和毒性的最佳预测指标。
- TDM在成人患者中获益仍存争议,但在儿童中应考虑,因个体间变异更高且达到目标概率更低。
临床怎么用
- 基于有限采样策略的多种贝叶斯估计器已开发,可用于临床中基于AUC的个体化剂量调整。
局限性
- 已发表的移植受者中更昔洛韦和缬更昔洛韦药动学及暴露/疗效或暴露/安全性关系研究较少。
- 关于TDM应使用的暴露参数仍存在争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ganciclovir and valganciclovir are first choice drugs for the prevention and treatment of cytomegalovirus infection and disease in solid organ and stem cell transplant recipients. Only a few studies on the pharmacokinetics and exposure/efficacy or exposure/safety relationships of ganciclovir and valganciclovir in transplant recipients have been published so far, and there are still controversies about the exposure parameter to use for therapeutic drug monitoring (TDM). We performed an extensive literature review of the clinical pharmacokinetics data, the exposure/effect relationships in terms of efficacy and safety, and the available tools for valganciclovir and ganciclovir TDM in adults and pediatrics transplant recipients. The pharmacokinetics of ganciclovir and valganciclovir is well described in adults and children, and a high interindividual variability is commonly observed. In contrast, the drug pharmacodynamics has been poorly described in adults and barely in children. The average 24-hour area under the concentration-time curve (AUC0-24h ) seems to be the best predictor of efficacy and toxicity. The benefit of TDM remains controversial in adult patients but should be considered in children due to higher interindividual variability and lower probability of target attainment. Several bayesian estimators based on limited sampling strategies have been developed with this aim and may be used in clinical practice for the AUC-based individual dose adjustment of ganciclovir and valganciclovir.
引用
- Franck B, Autmizguine J, Marquet P, et al. Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation. Clin Pharmacol Ther. 2021. PMID: 34596243. doi:10.1002/cpt.2431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。